MannKind

Why MannKind Is Up Big Today
Why MannKind Is Up Big Today
Motley Fool
MannKind
inhaled insulin
Afrezza
Flag link:
MannKind (MNKD) Q4 Revenues Rise 254%; Achieves First Ever Qtr Afrezza Gross Profit
MannKind (MNKD) Q4 Revenues Rise 254%; Achieves First Ever Qtr Afrezza Gross Profit
Street Insider
MannKind
earnings
Afrezza
Flag link:
FDA’s OPDP Warns MannKind for Facebook Post
FDA’s OPDP Warns MannKind for Facebook Post
RAPS.org
Afrezza
warning letter
FDA
OPDP
Facebook
social media
diabetes
MannKind
Flag link:
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Endpoints
MannKind
United Therapeutics
PAH
Treprostinil
Flag link:
Can MannKind Corporation Avert Bankruptcy?
Can MannKind Corporation Avert Bankruptcy?
Motley Fool
MannKind
earnings
Afrezza
Flag link:
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase
Street Insider
MannKind
TreT
FDA
PAH
Flag link:
MannKind Q1 Results: The Good, the Bad, and the Ugly
MannKind Q1 Results: The Good, the Bad, and the Ugly
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Broke Down in April
Why MannKind Corporation Stock Broke Down in April
Motley Fool
MannKind
Flag link:
3 Bright Spots in MannKind Corporation's Q4 Update
3 Bright Spots in MannKind Corporation's Q4 Update
Motley Fool
MannKind
earnings
Flag link:
Why MannKind Corporation Stock Is Falling Back to Earth Today
Why MannKind Corporation Stock Is Falling Back to Earth Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Motley Fool
diabetes
Senseonics
Lexicon Pharmaceuticals
MannKind
Flag link:
Why MannKind Corporation Jumped Higher Today
Why MannKind Corporation Jumped Higher Today
Motley Fool
MannKind
diabetes
Afrezza
Flag link:
Why MannKind Corporation Dipped 4.8% in November
Why MannKind Corporation Dipped 4.8% in November
Motley Fool
MannKind
earnings
Flag link:
An Interview With MannKind CEO Michael Castagna
An Interview With MannKind CEO Michael Castagna
Motley Fool
MannKind
Michael Castagna
Flag link:
Is MannKind's Debt a Ticking Time Bomb?
Is MannKind's Debt a Ticking Time Bomb?
Motley Fool
MannKind
debt
Flag link:
3 Drug Stocks That Soared This Week
3 Drug Stocks That Soared This Week
Motley Fool
Endocyte
PSMA-617
MannKind
Afrezza
Mylan Labs
generics
Teva Pharmaceutical
Flag link:
FDA approves new label language for Afrezza
FDA approves new label language for Afrezza
Greenwich Citizen, CT
FDA
labeling
Afrezza
inhaled insulin
MannKind
diabetes
Flag link:
Why MannKind Stock Started October With a Bang
Why MannKind Stock Started October With a Bang
Motley Fool
MannKind
inhaled insulin
Afrezza
diabetes
Flag link:
MannKind - Afrezza Scripts Finish August Flat
MannKind - Afrezza Scripts Finish August Flat
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
MannKind posts mixed Q2
MannKind posts mixed Q2
Drug Delivery Business News
MannKind
earnings
Flag link:

Pages